CTHRepealedLegislation
National Health (Chemotherapy Pharmaceuticals Access Program) Special Arrangement 2010 (No. PB 117 of 2010)
Sch 3Circumstances and Purposes Codes
Start here
Get a plain-English read of Sch 3
Turn the raw legal text into a practical explanation grounded in National Health (Chemotherapy Pharmaceuticals Access Program) Special Arrangement 2010 (No. PB 117 of 2010).
Schedule 3 Circumstances and Purposes Codes
(sections 9, 18 and 20)
| Listed Drug | Circumstances Code | Purposes Code | Circumstances and Purposes | Authority Requirements- Part of Circumstances |
|---|---|---|---|---|
| Aprepitant | C3619 | Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy, in combination with a 5-hydroxytryptamine type 3 receptor antagonist and dexamethasone, where any 1 of the following chemotherapy agents are to be administered:(a) altretamine;(b) carmustine;(c) cisplatin, when a single dose constitutes a cycle of chemotherapy;(d) cyclophosphamide, at a dose of 1500 mg per square metre per day or greater;(e) dacarbazine;(f) procarbazine, when a single dose constitutes a cycle of chemotherapy;(g) streptozocin; andwhere treatment with aprepitant is limited to an initial dose of 125 mg and 2 subsequent doses of 80 mg per cycle of cytotoxic chemotherapy | Compliance with Authority Required procedures – Streamlined Authority Code 3619 | |
| C3620 | Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat breast cancer, in combination with a 5-hydroxytryptamine type 3 receptor antagonist and dexamethasone, where cyclophosphamide and an anthracycline are to be co-administered, and where treatment with aprepitant is limited to an initial dose of 125 mg and 2 subsequent doses of 80 mg per cycle of cytotoxic chemotherapy | Compliance with Authority Required procedures – Streamlined Authority Code 3620 | ||
| C3621 | Management of nausea and vomiting associated with moderately emetogenic cytotoxic chemotherapy being used to treat malignancy, in combination with a 5-hydroxytryptamine type 3 receptor (5HT3) antagonist and dexamethasone on day 1, where the patient has had a prior episode of chemotherapy induced nausea or vomiting where any 1 of the following intravenous chemotherapy agents is to be administered:(a) arsenic trioxide;(b) azacitidine;(c) carboplatin;(d) cyclophosphamide, at a dose of less than 1500 mg per square metre per day;(e) cytarabine, at a dose of greater than 1 g per square metre per day;(f) dactinomycin;(g) daunorubicin;(h) doxorubicin;(i) epirubicin;(j) fotemustine;(k) idarubicin;(l) ifosfamide;(m) irinotecan;(n) melphalan;(o) methotrexate, at a dose of 250 mg to 1 g per square metre;(p) oxaliplatin;(q) raltitrexed; andwhere treatment with aprepitant is limited to an initial dose of 125 mg and 2 subsequent doses of 80 mg per cycle of cytotoxic chemotherapy, and where concomitant use of a 5HT3 antagonist should not occur with aprepitant on days 2 and 3 of any chemotherapy cycle |